A Phase 3 trial of OMS721 in IgA nephropathy.
Phase of Trial: Phase III
Latest Information Update: 15 Aug 2017
At a glance
- Drugs OMS 721 (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- 15 Aug 2017 According to Omeros Corporation media release, company is working with FDA to finalize the protocol of a trial and expect to enroll patients by end of the year 2017.
- 16 Nov 2016 New trial record
- 31 Oct 2016 According to an Omeros Corporation media release, company plans to initiate this trial in 2017 if fast track designation is granted by FDA.